Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines

 Revance Therapeutics, Inc.  (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines.